Intellia Therapeutics, Inc announced that the first patient has been treated with NTLA-2001, which the company is developing as a single-course, potentially curative therapy for transthyretin amyloidosis (ATTR).

Oxford Immunotec Global PLC today announced the release of data from a prospective cohort study in keyworkers in the UK – a collaboration between the Company and Public Health England.

The seventh annual Movers and Shakers in BioBusiness report highlights 30 examples of resourceful leaders in the UK bioscience sector.

PerkinElmer, Inc. announced today that EUROIMMUN has launched the Anti-SARS-CoV-2 QuantiVacTM ELISA (IgG) to quantify IgG antibodies against the SARS-CoV-2 S1 antigen.

PhoreMost Limited and Oxford Biomedica plc today announced that they have entered into a discovery collaboration to develop next-generation CAR-T cell therapies.

Cytiva launches new services for diagnostic developers and will establish new labs to meet the future needs of the industry.

Thermo Fisher Scientific and Symphogen announce the extension of a strategic collaboration to deliver quality control workflows for the simplified analysis of complex therapeutic proteins and advance biopharmaceutical discovery and development.

PerkinElmer, Inc., today launched the life science industry’s first no-wash Ubiquitin phosphorylation at Serine 65 immunoassay that is aimed at helping scientists discover new therapeutic candidates earlier in the disease cycle.

AMSBIO announce a new rabbit and mouse recombinant monoclonal antibody development service based upon a revolutionary technology platform.

A project to develop surface treatments that can provide long-lasting protection against the COVID-19 virus has been launched at the University of Birmingham.